OACC
Oaktree Acquisition Corp. III Life Sciences
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
No implied move.
Next report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
Oaktree Acquisition Corp. III Life Sciences
Expected move
No implied move.
Next report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
No changes.
No changes.
| Manager | Value | % base | |
|---|---|---|---|
| CNH Partners | $14.2M | 7.80% | 0.00% |
| Fort Baker | $11.8M | 6.51% | +10.54% |
| Decagon | $11.7M | 6.42% | +8.87% |
| Empyrean Capital Partners | $9.6M | 5.30% | 0.00% |
| D. E. Shaw | $9.2M | 5.08% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| CNH Partners | $14.2M | 7.80% | 0.00% |
| Fort Baker | $11.8M | 6.51% | +10.54% |
| Decagon | $11.7M | 6.42% | +8.87% |
| Empyrean Capital Partners | $9.6M | 5.30% | 0.00% |
| D. E. Shaw | $9.2M | 5.08% | 0.00% |
Same SIC code · 6
Same SEC industry code: Innventure, Inc., Artius II Acquisition Inc., Armada Acquisition Corp. III and 3 more; no measured co-movers for Oaktree Acquisition Corp. III Life Sciences.
Same SIC code · 6
Same SEC industry code: Innventure, Inc., Artius II Acquisition Inc., Armada Acquisition Corp. III and 3 more; no measured co-movers for Oaktree Acquisition Corp. III Life Sciences.
Annual filing, covered
10-K parsed · Mar 26 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 26 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Oaktree Acquisition Corp. III Life Sciences
10.68
−0.04 · −0.37%
post 10.75 +0.65%
We are a newly organized blank check company incorporated on June 28, 2024, as a Cayman Islands exempted company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. We have generated no operating revenues to date and we do not expect that we will generate operating revenues until we consummate our initial business combination. While we may pursue an acquisition opportunity in any business, industry, sector, or geographical location, we intend to focus on industries that complement our management team’s background, and to capitalize on the ability of our management team to identify and acquire a business, focusing on the healthcare or healthcare-related industries. In particular, we intend to target North American, British or European companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors where our management has extensive investment experience. Our executive offices are located at 333 South Grand Avenue, 28th Floor, Los Angeles, California 90071.
We are a newly organized blank check company incorporated on June 28, 2024, as a Cayman Islands exempted company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. We have generated no operating revenues to date and we do not expect that we will generate operating revenues until we consummate our initial business combination. While we may pursue an acquisition opportunity in any business, industry, sector, or geographical location, we intend to focus on industries that complement our management team’s background, and to capitalize on the ability of our management team to identify and acquire a business, focusing on the healthcare or healthcare-related industries. In particular, we intend to target North American, British or European companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors where our management has extensive investment experience. Our executive offices are located at 333 South Grand Avenue, 28th Floor, Los Angeles, California 90071.